Mankind Pharma has reported result for second quarter ended September 30, 2025 (Q2FY26).
The company has reported 28.89% decline in its net profit at Rs 458.90 crore for the quarter ended September 30, 2025 as compared to Rs 645.34 crore for the same quarter in the previous year. However, total income of the company increased marginally by 1.31% at Rs 2,686.45 crore for Q2FY26 as compared to Rs 2,651.66 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 21.05% decline in its net profit at Rs 520.18 crore for Q2FY26 as compared to Rs 658.88 crore for the same quarter in the previous year. However, the total income of the company increased by 19.51% at Rs 3,789.03 crore for Q2FY26 as compared to Rs 3,170.49 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: